Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 50Stomach Neoplasms 7Neoplasm Metastasis 5Colorectal Neoplasms 4Uterine Cervical Neoplasms 3HER2-positive Breast Cancer 3Esophageal Neoplasms 3Uterine Neoplasms 2Solid Tumors 2Lung Neoplasms 2Inflammatory Breast Neoplasms 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Brain Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Adenocarcinoma Of Esophagus 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Patient Compliance 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1

Interventions

Specimen Handling 4Biopsy 3X-Rays 2trastuzumab biosimilar HLX02 1pertuzumab 1erdafitinib 1copanlisib 1Trastuzumab 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Iohexol 1Carboplatin 1CT-P6 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Malignant Solid Neoplasm × Trastuzumab × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡